← Back to Search

Placebo

Smoker Solarplast for Immunity

N/A

Waitlist Available

Led By Richard Bloomer, PhD

Research Sponsored by University of Memphis

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 60 days of treatment

Awards & highlights

Study Summary

The purpose of this study is to determine the impact of Solarplast treatment on measures of oxidative stress, immune function, skin appearance, and associated measures in 60 men and women, consisting of both cigarette smokers and nonsmokers. The hypothesis is that the Solarplast treatment will reduce oxidative stress biomarkers and favorably impact immune measures and both perceived and quantifiable measures of skin health, in both smokers and non-smokers, with a greater impact observed in smokers. Photographic analyses like the Pear Plus 3D system have been developed for clinical use for monitoring skin health.

Eligible Conditions

Immunity
Smoking/Cigarette Smoking

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 60 days of treatment

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~60 days of treatment

This trial's timeline: 3 weeks for screening, Varies for treatment, and 60 days of treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Lipid peroxidation

Plasma Cytokine Panel

Plasma Cytokine Panel on LPS treated whole blood

+5 more

Secondary outcome measures

Food Logs

Resting blood pressure

Trial Design

4Treatment groups

Experimental Treatment

Placebo Group

Group I: Smoker SolarplastExperimental Treatment1 Intervention

Smoker's assigned to solarplast

Group II: Non-smoker SolarplastExperimental Treatment1 Intervention

Non-smoker assigned to solarplast

Group III: Smoker PlaceboPlacebo Group1 Intervention

Smoker's assigned to placebo

Group IV: Non-smoker PlaceboPlacebo Group1 Intervention

Non-smoker assigned to placebo

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

100 mg Solarplast

2021

N/A

~50

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of MemphisLead Sponsor

70 Previous Clinical Trials

11,839 Total Patients Enrolled

Deerland Probiotics and EnzymesUNKNOWN

2 Previous Clinical Trials

160 Total Patients Enrolled

Richard Bloomer, PhDPrincipal InvestigatorUniversity of Memphis

16 Previous Clinical Trials

439 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available openings for individuals to participate in this research?

"As of 10/17/2022, this medical trial is actively seeking out participants. Originally posted on October 22nd 2021, the details have been modified in recent times."

Answered by AI

How many participants are being monitored during this clinical experiment?

"Affirmative. Clinicaltrials.gov's information alludes to the recruitment process of this trial, which was initially posted on October 22nd 2021 and most recently updated on October 17th 2022. A maximum of 60 subjects are sought from a single centre."

Answered by AI

Does the age restriction on this research study extend below 35 years?

"This clinical trial is only applicable to individuals between the ages of 30 and 60. For those under 18, there are 2 studies available; elderly persons over 65 have access to 34 trials."

Answered by AI

Are there any specific criteria for enrollment in this research trial?

"This investigation is recruiting a cohort of 60 adults aged between 30 and 60 who frequently use tobacco products. Eligibility requirements include body mass index (BMI) from 18-40 kg/m2, non-pregnant female participants, smokers smoking at least 5 cigarettes per day for the past 12 months with mild skin irritations, no exposure to second hand smoke in the last year or having used any smoked product such as marijuana in the same time frame, absence of active infection or illness and being able to fast overnight for 10-12 hours."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Impact of Solarplast® on Immunity in Active Smokers and Non-smokers

Richard Bloomer 2021. "Impact of Solarplast® on Immunity in Active Smokers and Non-smokers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05162820.